Pharmaceutical composition for use in treating cognitive decline or for use in treating overweight or obesity
US-2024398775-A1 · Dec 5, 2024 · US
Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
US2019105310A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019105310-A1 |
| Application number | US-201816211839-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 6, 2018 |
| Priority date | Jan 10, 2014 |
| Publication date | Apr 11, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
First claim
Opening claim text (preview).
1 . A pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.001 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof. 2 . The pharmaceutical preparation according to claim 1 , comprising 0.001 to 0.003% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof. 3 . An eye drop comprising the pharmaceutical preparation of claim 1 . 4 . A method for treatment or prevention of glaucoma or ocular hypertension, comprising administrating the pharmaceutical preparation of claim 1 to a patient who needs the treatment or prevention of glaucoma or ocular hypertension, wherein the pharmaceutical preparation is instilled once or twice a day. 5 . A method for treatment or prevention of glaucoma or ocular hypertension, comprising administrating the pharmaceutical preparation of claim 1 to a patient who needs the treatment or prevention of glaucoma or ocular hypertension, wherein a dose of one or two drops is instilled. 6 . A method for treatment or prevention of glaucoma or ocular hypertension, comprising administrating the pharmaceutical preparation of claim 1 to a patient who needs the treatment or prevention of glaucoma or ocular hypertension, wherein a dose of one drop is instilled once a day.
Assignees
Inventors
Classifications
Antiglaucoma agents or miotics · CPC title
- A61K31/444Primary
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Ophthalmic agents · CPC title
Eye, e.g. artificial tears · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019105310A1 cover?
- Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
- Who is the assignee on this patent?
- Santen Pharmaceutical Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/444. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Apr 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).